Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Mangia A, Bányai T, De Bartolomeo G, Gervain J, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M. Mangia A, et al. Among authors: ouzan d. Liver Int. 2014 Aug;34(7):e217-28. doi: 10.1111/liv.12352. Epub 2013 Nov 20. Liver Int. 2014. PMID: 24251988
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M. Marcellin P, et al. Among authors: ouzan d. Hepatology. 2012 Dec;56(6):2039-50. doi: 10.1002/hep.25892. Epub 2012 Aug 8. Hepatology. 2012. PMID: 22706730 Clinical Trial.
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, Ouzan D, Papatheodoridis G, Ramji A, Borgia SM, Wedemeyer H, Losappio R, Pérez-Hernandez F, Wick N, Brown RS Jr, Lampertico P, Doucette K, Ntalla I, Ramroth H, Mertens M, Vanstraelen K, Turnes J. Mangia A, et al. Among authors: ouzan d. Liver Int. 2020 Aug;40(8):1841-1852. doi: 10.1111/liv.14537. Epub 2020 Jun 9. Liver Int. 2020. PMID: 32449966 Free PMC article.
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F, Truchi R, Combis JM, Bailly F, Rosa I, Hézode C, Glorian-Petraud D, Libert O, Ramroth H, Asselah T, Thiefin G, Roulot D, Roche B, Leroy V, Dumortier J, Thabut D, Pol S; HELIOS study group. Ouzan D, et al. Dig Dis Sci. 2021 Mar;66(3):881-898. doi: 10.1007/s10620-020-06234-1. Epub 2020 Apr 18. Dig Dis Sci. 2021. PMID: 32303953
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour JF, Bourlière M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Kukolj G, Datsenko Y, Garcia M, Scherer J, Quinson AM, Stern JO; STARTVerso1 Study Group. Ferenci P, et al. Among authors: ouzan d. J Hepatol. 2015 Jun;62(6):1246-55. doi: 10.1016/j.jhep.2014.12.024. Epub 2015 Jan 2. J Hepatol. 2015. PMID: 25559324 Free article. Clinical Trial.
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
Marcellin P, Xie Q, Woon Paik S, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M, Ouzan D, Foster GR, Papatheodoridis G, Messinger D, Regep L, Bakalos G, Alshuth U, Lampertico P, Wedemeyer H. Marcellin P, et al. Among authors: ouzan d. PLoS One. 2020 Apr 10;15(4):e0230893. doi: 10.1371/journal.pone.0230893. eCollection 2020. PLoS One. 2020. PMID: 32275726 Free PMC article.
169 results